Appendix 4c quarterly activity report for quarter ended march 31, 2025

New york, april 29, 2025 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended march 31, 2025.

MESO Ratings Summary

MESO Quant Ranking